Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:32 PM
Ignite Modification Date:
2025-12-24 @ 11:32 PM
NCT ID:
NCT00002756
Eligibility Criteria:
DISEASE CHARACTERISTICS:
* Newly diagnosed acute lymphoblastic leukemia (ALL) or acute undifferentiated leukemia
* No infants less than 36 weeks' gestation
* CNS or testicular disease permitted
* No B-cell ALL or acute myeloid leukemia
* Previously untreated except for the following:
* Steroid treatment within 48 hours of diagnosis allowed with physical examination and differential CBC immediately prior to beginning steroids
* Concurrent registration on protocol POG-9900 (ALL classification study) required
* Patients registered on POG-9407 are eligible for the pharmacokinetic part of the study
PATIENT CHARACTERISTICS:
Age:
* Under 1 at diagnosis
Performance status:
* Not specified
Life expectancy:
* Not specified
Hematopoietic:
* Not specified
Hepatic:
* Not specified
Renal:
* Not specified
Other:
* No uncontrolled infection
* Adequate major organ function
PRIOR CONCURRENT THERAPY:
Biologic therapy:
* Not specified
Chemotherapy:
* Not specified
Endocrine therapy:
* See Disease Characteristics
* No concurrent chronic steroid treatment
Radiotherapy:
* Not specified
Surgery:
* Not specified
Other:
* No other concurrent anticancer therapy
Healthy Volunteers:
False
Sex:
ALL
Maximum Age:
1 Year
Study:
NCT00002756
Study Brief:
Protocol Section:
NCT00002756